BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Leerink Partners Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $85
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $73
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $61
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $77
Ultragenyx Pharma Price Target Maintained With a $116.00/Share by Cantor Fitzgerald
Ultragenyx Pharmaceutical Analyst Ratings
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Bank of America Securities
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
Ultragenyx Pharmaceutical Analyst Ratings
Truist Financial Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Ultragenyx Pharmaceutical (RARE) Receives a Buy From Barclays
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $67 to $127
Ultragenyx Pharma Price Target Raised to $75.00/Share From $72.00 by Wells Fargo
Ultragenyx Pharmaceutical Analyst Ratings
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $46 to $135